Abstract: Objective  To evaluate the efficacy and safety of LCZ696 in the treatment of heart failure by searching  its RCTs at home and abroad.Methods  The Cochrane library,  Pubmed,  Web of science,  CNKI,  VIP,  Wanfang database  were searched for literatures on  LCZ696 for heart failure. And the literature were screened according to the  inclusion and exclusion criteria.The bias risk assessment tool in Cochrane intervention system evaluation manual version 5.1.0 was used to evaluate the quality of included studies,  and RevMan 5.3 software was used to conduct the metaanalysis of all  outcome indexes.Results  A total of 14  967 patients were enrolled in 6 RCTs studies. Combined outcome indicators showed that  LCZ696,  LAVI ( WMD=-2.18,  95%CI［-3.63, -0.74］,  P=0.003),  E/e'  (WMD=-1.01,  95%CI［-1.89, -0.12］,  P=0.03),  mortality (RR=0.89,  95%CI［0.83, 0.96］, P=0.003),  the rate of rehospitalization for heart failure  (RR=0.83,  95%CI［0.78,  0.88］, P<0.01)  decreased more significantly after the treatment,  while the quality of life score  (WMD=1.32,  95%CI［0.69, 1.95］,  P<0.01)  and the incidence of symptomatic hypotension　(RR=1.46,  95%CI［1.34, 1.60］,  P<0.01)   increased more significantly.ConclusionLCZ696 can significantly reduce the mortality and rehospitalization rate of patients with heart failure,  and it does not increase the  risk of adverse events such as renal injury,  angioedema and hyperkalemia.

Key words: heart failure, LCZ696, meta analysis